This is an amended filing
OliX Pharmaceuticals, Inc. OLX10212 New Zealand Phase 2a Trial Application Approved on Re-review After Rejection
AI summary · Not investment advice
The New Zealand ethics committee approved on Nov 10, 2026 on re-review the OLX10212 Phase 2a application it had rejected on Oct 12, 2026.
Commentary
AI commentary · Not investment advice
What happened
Olix Pharmaceuticals won approval for a Phase 2a clinical trial in New Zealand after an appeal. The Northern B Health and Disability Ethics Committee had earlier rejected the application. The company sought a re-review, and the committee approved it this time.
In the company's terms
The trial targets age-related macular degeneration (AMD) with bilateral geographic atrophy (GA). Geographic atrophy is a condition in which retinal cells gradually die off. A Phase 2a trial is an early step that looks at whether a drug may work.
What changes for shareholders
One more approval is still needed. MedSafe, New Zealand's clinical trial approval authority, must approve the clinical trial plan. The materials do not say when that approval will come.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
O